Monday, March 15, 2010

NGM Biopharmaceuticals Get $51M

South San Francisco-based NGM Biopharmaceuticals said today that it has closed on the first tranche of a $51, Series B round of funding. The round came from The Column Group, Tichenor Ventures, LLC, Prospect Venture Partners, Rho Ventures, and others. According to NGM, it has named McHenry (Mac) T. Tichenor, Jr. to its board as part of the funding. Tichenor is a Managing Member of Tichenor Ventures. NGM is targeting biopharmaceuticals to help restore glucose balance in patients with type 2 diabetes. More information »